Abstract:

Objective　To explore the current situation of pediatric oral Chinese patent medicine and analyze its prescription medication. Methods　A total of 300 pediatric oral Chinese patent medicine prescriptions screened by the hospital information system of Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Preparatory Stage) from January 2022 to December 2022 were selected for the research. There were 168 boys and 132 girls, aged ≤12 years old. The dosage form, age distribution, combined use, action category, and unreasonable prescription composition were analyzed. Results　Among the 300 prescriptions in this study, the proportion of granules was the highest [51.77% (322/622)], followed by oral liquid [31.35% (195/622)] and tablets [9.00% (56/622)], and the proportion of capsules was the lowest [7.72% (48/622)]. The proportion of >1 - ≤3 years old group was the highest [29.00% (87/300)], followed by ≤1 year old group [14.67% (44/300)], >3 - ≤6 years old group [27.67% (83/300)], >6 - ≤9 years old group [13.67% (41/300)], and >9 - ≤12 years old group [15.00% (45/300)]. Among the combined medication, the proportion of double combinations was the highest [37.33% (112/300)], followed by single drug [30.67% (92/300)], triple combinations [26.00% (78/300)], and quadruple combinations or more [6.00% (18/300)]. Among the action categories, clearing heat and detoxifying accounted for the highest proportion [37.94% (236/622)], followed by dispelling wind and relieving exterior [26.69% (166/622)], relieving cough, resolving phlegm and relieving asthma [20.10% (125/622)], and regulating spleen and stomach [10.45% (65/622)]. The proportion of irrational prescriptions was 2.00% (6/300) of inappropriate indications, 1.33% (4/300) of inappropriate usage and dosage, 1.00% (3/300) of repeated medication, and 0.67% (2/300) of incompatibility. Conclusions　In pediatric oral Chinese patent medicine prescriptions, there are some unreasonable phenomena such as unreasonable combination of Chinese patent medicine prescriptions. The hospitals need to strengthen the management of the use of oral Chinese patent medicines to ensure the medication safety.

Key words:

Pediatrics, Oral administration, Chinese patent medicine, Current situation, Prescription medication

摘要：

目的　探讨儿科口服中成药的现状，分析其处方用药。方法　选择2022年1月至2022年12月上海交通大学医学院附属松江医院（筹）信息系统筛选的300张儿科口服中成药处方进行研究，患儿男168例次、女132例次，年龄≤12岁。分析剂型、年龄分布情况、联用情况、作用类别、不合理处方构成情况。结果　本次研究300张处方中颗粒剂占比最高，为51.77%（322/622），口服液占比31.35%（195/622），片剂占比9.00%（56/622），胶囊占比最少，为7.72%（48/622）。>1～≤3岁年龄段占比最高，为29.00%（87/300），≤1岁占比14.67%（44/300），>3～≤6岁占比27.67%（83/300），>6～≤9岁占比为13.67%（41/300），>9～≤12岁占比为15.00%（45/300）。联合用药中，二联占比最高，为37.33%（112/300），单药占比30.67%（92/300），三联占比26.00%（78/300），四联及以上占比6.00%（18/300）。作用类别中，清热解毒占比最高，为37.94%（236/622），祛风解表占比26.69%（166/622），止咳化痰平喘占比20.10%（125/622），调理脾胃占比10.45%（65/622）。不合理处方占比分别为适应证不适宜2.00%（6/300），用法用量不适宜1.33%（4/300），重复用药1.00%（3/300），配伍禁忌0.67%（2/300）。结论　在儿科口服中成药处方中，存在中成药处方联合用药不合理等现象，医院需加强对口服中成药使用的管理，保证患儿用药安全。

关键词:

儿科, 口服, 中成药, 现状, 处方用药